Significant bronchodilator responsiveness and "reversibility" in a population sample
- PMID: 20854046
- DOI: 10.3109/15412555.2010.510161
Significant bronchodilator responsiveness and "reversibility" in a population sample
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is defined by being "not fully reversible", most guidelines recommend measurement of lung function after the administration of a bronchodilator. The objective of this study was to compare bronchodilator responsiveness (significant improvement in the FEV(1) or FVC) to full-, partial- or "inverse'" reversibility in obstruction status in a population-based sample in Southeastern Kentucky. The study population was selected using random digit dialing of an adult population in Southeastern Kentucky as part of the Burden of Lung disease (BOLD) project. Lung function was assessed using spirometry pre- and post-bronchodilation. Subjects presence and severity of COPD was classified using modified Global Obstructive Lung Disease (GOLD) criteria. We examined the relation between changes in "obstruction" status (based on the FEV(1)/ FVC of 0.7) and the presence of "significant bronchodilator responsiveness" (based on ≥ 12% improvement in the FEV(1) or the FVC). The final population with acceptable pre- and post-bronchodilator spirometry included 440 participants. 32/440 subjects (7.3%) changed from obstructed to unobstructed (full-reversibility), 19/440 (4.3%) changed from unobstructed to obstructed ("inverse"-reversibility), 389/440 (88.4%) had either no-change or partial-reversibility, and 65/440 (14.8%) had bronchodilator responsiveness. Among those with full-reversibility, only 9/32 (28.1%) had bronchodilator responsiveness, whereas among subjects with "inverse"-reversibility, 10/19 (52.6%) had bronchodilator responsiveness. Among all subjects with bronchodilator responsiveness, only 19/65 (29.2%) changed categories. Our findings suggest that significant bronchodilator responsiveness is not the same as "reversibility" of "obstruction", even though these terms are often used interchangeably.
Similar articles
-
[Comparison of lung volume response with airflow response to bronchodilator in patients with chronic obstructive pulmonary disease].Zhonghua Jie He He Hu Xi Za Zhi. 2010 Feb;33(2):109-13. Zhonghua Jie He He Hu Xi Za Zhi. 2010. PMID: 20367950 Chinese.
-
The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.Pulm Pharmacol Ther. 2008 Oct;21(5):767-73. doi: 10.1016/j.pupt.2008.04.005. Epub 2008 May 6. Pulm Pharmacol Ther. 2008. PMID: 18555715
-
Impact of bronchodilator use on the prevalence of COPD in population-based samples.COPD. 2007 Jun;4(2):113-20. doi: 10.1080/15412550701341012. COPD. 2007. PMID: 17530504
-
Bronchodilator reversibility in COPD.Chest. 2011 Oct;140(4):1055-1063. doi: 10.1378/chest.10-2974. Chest. 2011. PMID: 21972384 Review.
-
Diagnosis and treatment of patients with chronic obstructive pulmonary disease in the primary care setting: focus on the role of spirometry and bronchodilator reversibility.J Fam Pract. 2011 Apr;60(4 Suppl Diagnosis):S9-16. J Fam Pract. 2011. PMID: 21472146 Review. No abstract available.
Cited by
-
Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2015 Jun 19;10:1191-7. doi: 10.2147/COPD.S82509. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26150710 Free PMC article.
-
Bronchodilator responsiveness or reversibility in asthma and COPD - a need for clarity.Int J Chron Obstruct Pulmon Dis. 2018 Oct 23;13:3511-3513. doi: 10.2147/COPD.S183736. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30498341 Free PMC article. No abstract available.
-
The Effectiveness and Harms of Screening for Chronic Obstructive Pulmonary Disease: An Updated Systematic Review and Meta-Analysis.J Korean Med Sci. 2022 Apr 11;37(14):e117. doi: 10.3346/jkms.2022.37.e117. J Korean Med Sci. 2022. PMID: 35411733 Free PMC article.
-
Computed tomography structural lung changes in discordant airflow limitation.PLoS One. 2013 Jun 13;8(6):e65177. doi: 10.1371/journal.pone.0065177. Print 2013. PLoS One. 2013. PMID: 23785411 Free PMC article.
-
Is It Time to Abandon the Postbronchodilator Requirement in Defining Chronic Obstructive Pulmonary Disease?Am J Respir Crit Care Med. 2022 Sep 1;206(5):522-524. doi: 10.1164/rccm.202204-0802ED. Am J Respir Crit Care Med. 2022. PMID: 35579677 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical